Last reviewed 2026-05-14 · How we verify

Meningococcal conjugate vaccine GSK134612

Meningococcal conjugate vaccine GSK134612 is a Meningococcal conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive meningococcal disease.

This conjugate vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide capsules by linking them to a protein carrier.

This conjugate vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide capsules by linking them to a protein carrier. Used for Prevention of invasive meningococcal disease.

At a glance

Mechanism of action

Meningococcal conjugate vaccines work by conjugating polysaccharide antigens from the meningococcal capsule to a protein carrier, which enhances T-cell dependent immune responses and improves immunogenicity compared to unconjugated polysaccharide vaccines. This approach generates both antibody and cellular immunity, providing protection against invasive meningococcal disease caused by the targeted serogroups. GSK134612 is designed to provide broad coverage against multiple meningococcal serogroups.

Approved indications

• Prevention of invasive meningococcal disease

Common side effects

• Injection site pain
• Injection site erythema
• Injection site swelling
• Fever
• Myalgia
• Fatigue

Key clinical trials

• Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine (PHASE3)
• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
• Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children (PHASE3)
• Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children (PHASE3)
• Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children (PHASE3)
• Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination (PHASE3)
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers (PHASE3)
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Meningococcal conjugate vaccine GSK134612 CI brief — competitive landscape report
• Meningococcal conjugate vaccine GSK134612 updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI

Frequently asked questions about Meningococcal conjugate vaccine GSK134612

Related

• Drug class: All Meningococcal conjugate vaccine drugs
• Target: All drugs targeting Meningococcal polysaccharide capsule antigens
• Manufacturer: GlaxoSmithKline — full pipeline
• Therapeutic area: All drugs in Immunology / Infectious Disease
• Indication: Drugs for Prevention of invasive meningococcal disease
• Compare: Meningococcal conjugate vaccine GSK134612 vs similar drugs
• Pricing: Meningococcal conjugate vaccine GSK134612 cost, discount & access